Pembrolizumab biosimilar is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is an IgG4 kappa immunoglobulin with an approximate molecular weight of 149 kDa.
Pembrolizumab biosimilar is supplied at a concentration of 25 mg/mL as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, which contains 1.55 mg/mL L-histidine, 0.2 mg/mL polysorbate 80, 70 mg/mL sucrose, and Water for Injection.
Statement: this product is used for R&D only, not for clinical usage.
|
Name
|
Pembrolizumab biosimilar
|
|
CAS NO.
|
1374853-91-4
|
|
Type
|
Whole antibody
|
|
Source
|
Humanized (from mouse)
|
|
Target
|
PD-1
|
|
Clone
|
Monoclone
|
|
Molecular Weight
|
149 kDa
|
|
Formula
|
C6534H10004N1716O2036S46
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..
Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.
Topwell aims to become a global leader in pharmaceutical & chemical industry.
中文
